Created: 2024-04-02T15:42:13.591470
Name: Submitting_risk_management_plans_draft_guidance_document:_RMP_summary_template
Original URL: https://www.canada.ca/en/health-canada/programs/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices/submitting-risk-management-plans/summary-template.html
Package ID: 43d098a2-19ea-4296-bbad-b01f2b4e9f70
Keywords: ['risk management plans', 'RMP', 'submitting RMP', 'risks', 'uncertainties of drug-products', 'procedures to submit', 'RMP summary template']
Notes: The RMP summary should include specific sections, which mirror the EU RMP Summary format sections.
-------------------------------
Extracted Text:
Submitting risk management plans guidance document: RMP summary template - Canada.ca Skip to main content Skip to "About government" Language selection Français fr / Gouvernement du Canada Search Search Canada.ca Search Menu Main Menu Jobs and the workplace Immigration and citizenship Travel and tourism Business and industry Benefits Health Taxes Environment and natural resources National security and defence Culture, history and sport Policing, justice and emergencies Transport and infrastructure Canada and the world Money and finances Science and innovation You are here: Canada.ca Health Health system and services Health-related consultations Consultation on proposed agile regulations and guidance for licensing drugs and medical devices Submitting risk management plans guidance document: Introduction Submitting risk management plans draft guidance document: RMP summary template Introduction Procedures to submit RMP summary template Canadian-specific addendum template Opioid products Contact us On this page Summary specifications Introductory paragraph The drug and what it is used for Associated risks and minimization measures Summary specifications The RMP summary should include specific sections, which mirror the EU RMP Summary format sections. These are: an introductory paragraph the drug and what it is used for risks and uncertainties associated with the drug and measures to: prevent or reduce the risks address and monitor the uncertainties In the event that 1 or more of the sections do not apply, they should still be included in the RMP summary with a notation that the section is not applicable. It is insufficient to submit an EU RMP summary as submitted for another jurisdiction. This is because the summary must contain Canadian-specific considerations and must be provided in both English and French. For a template of the EU RMP summary, refer to: Guidance on the format of the risk management plan (RMP) in the EU – in integrated format Introductory paragraph The introductory paragraph should indicate the purpose of the document and the name of the product. It is suggested that the following text template be used, which is the text template used in the EU RMP template, modified for Canada: "This is a summary of the risk management plan (RMP) for [product name]. The RMP details important risks of [product name], [how these risks can be reduced or prevented] and how more information will be obtained about [product name]'s risks and uncertainties (missing information). [Product name]'s product monograph and its patient medication information give essential information to health care professionals and patients on how [product name] should be used." The drug and what it is used for In this section, provide in paragraph form the: name of the active substances approved indication(s) of the drug in Canada route of administration of the product as reflected in the Canadian market authorization Associated risks and minimization measures Itemize routine risk minimization measures and state if the product has: routine or additional pharmacovigilance measures additional risk minimization measures missing information List of important risks and missing information In this section, provide a list of the: important identified risks important potential risks missing information The list should contain all the important risks and missing information from the RMP, including Canadian-specific considerations. The list should be presented in a table format for ease of reference. Sample table for list of important risks and missing information List of important risks and missing information Important identified risks - - - Important potential risks - - - Missing information - - - Summary of important risks Provide a separate table for each important identified risk and important potential risk. In each table, provide a summary of: evidence for linking the risk to the drug risk factors and risk groups risk minimization measures additional pharmacovigilance measures, if applicable Provide a separate table for each missing information. In each table, provide a summary of: risk minimization measures additional pharmacovigilance measures, if applicable The summary of each important risk should contain information from the RMP, including Canadian-specific considerations. Sample table for important identified risks important potential risks Important identified risk or important potential risk Insert risk as indicated in List of important risks and missing information Evidence for linking the risk to the drug Risk factors and risk groups Risk minimization measures Routine and additional measures Additional pharmacovigilance measures Sample table for missing information Missing information Insert missing information as indicated in List of important risks and missing information Risk minimization measures Additional pharmacovigilance measures Page details Date modified: 2022-12-16 About this site Health Canada Contact us Government of Canada All contacts Departments and agencies About government Themes and topics Jobs Immigration and citizenship Travel and tourism Business Benefits Health Taxes Environment and natural resources National security and defence Culture, history and sport Policing, justice and emergencies Transport and infrastructure Canada and the world Money and finances Science and innovation Indigenous Peoples Veterans and military Youth Government of Canada Corporate Social media Mobile applications About Canada.ca Terms and conditions Privacy